News

Vibrent Health Integrates Electronic Health Records into its Digital Research Platform, Empowering Participants to Share Their Data for Clinical Research

New framework based on HL7 Fast Healthcare Interoperability Resources (FHIR) gives Standards based access to EHR data to accelerate clinical research and digital trials

FAIRFAX, Va. — Vibrent Health, a health technology startup powering the future of precision health research, announced the integration of electronic health record (EHR) data into its Digital Health Solutions Platform, a platform that enables collection of health data from broad sources including biospecimens, genomics, environment, lifestyle and behavior, and wearable device data for clinical research and trials. Vibrent Health supports leading FHIR-enabled EHR vendors such as Epic and Cerner to ensure that their systems are seamlessly interoperable with the DHS Platform. 

Access to EHR data removes barriers to health research and offers researchers valuable insight,” explained Mark Begale, vice president, Vibrent Health. “Transparent, secure access to the full history of a participant’s medical record is key to gathering whole-person data which is essential to advancing precision medicine.”

Vibrent Health’s EHR integration tools were developed to support the National Institutes of Health’s 10-year, million-person All of Us Research Program, for which Vibrent Health serves as the Participant Technology Systems Center. 

When a health research participant consents to sharing their EHR for research, Vibrent Health’s EHR tools enable researchers to access a wealth of health data via the DHS Platform.  This data can include information about diagnoses, treatments, medications, lab results and other health-related information that can provide a fuller and more accurate picture of a research participant’s health than data that is collected by researchers manually.

“Our platform’s EHR integration is built using the emerging standard of HL7 Fast Healthcare Interoperability Resources (FHIR) to give researchers the ability to access clinical records of various participants and combine that data with other data sources,” said Vibrent Health CEO Praduman “PJ” Jain. “Reusing data collected from participants’ clinical visits to health care providers helps to improve patient participation and provides the real-world evidence needed to accelerate health research.”

A major step to transformative precision medicine research, using EHR data in clinical research has the potential to bring new therapies to patients sooner and at lower cost. Access to data promises to improve safety, patient-centeredness, communication, education and equity. 

“We regularly hear from researchers that they want to access this critical data, but the costs are simply too high. Easier access to EHR integration could be the key to making a scientific discovery,” said Begale.

Recent News

07/23/2026

Activation Capital Expands the Bio+Tech Center, Doubling Laboratory Capacity to Strengthen Virginia’s Life Sciences Entrepreneurship and Innovation Ecosystem

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced an expansion of its Bio+Tech Center to support the continued growth of life sciences entrepreneurship across the region. Activation Capital’s Bio+Tech Center is a life sciences incubator located within the Virginia Bio+Technology Research Park. Serving as both a physical and programmatic

07/22/2026

Epidarex Announces Leadership Appointments

With the launch of our latest fund, Epidarex Capital IV, LP, we are pleased to announce several promotions. As we continue to grow and deepen our impact across the US and UK life science ecosystems, recognizing and elevating exceptional talent within our team is a vital part of that journey. These transitions reflect our continued

07/22/2026

Phlow Corp. Appoints Sripathy Venkatraman, Ph.D, As Chief Scientific Officer

Phlow Corp., a U.S.-based advanced pharmaceutical contract development and manufacturing organization (CDMO), dedicated to strengthening the nation’s pharmaceutical supply chain and protecting America’s medicine cabinet, today announced the appointment of Sripathy Venkatraman, Ph.D., MBA, as Chief Scientific Officer. Venkatraman brings more than 25 years of experience in pharmaceutical development, process chemistry, manufacturing, and scientific leadership. He